---
title: "Immunic raises USD 200 million in private placement, with potential for up to USD 200 million more. Funds to support Phase 3 trials and transition to commercial-stage company."
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/275895038.md"
description: "An initial sum of $200 million has been received upfront, with the possibility of an additional $200 million in proceeds. This funding is anticipated to cover the costs associated with finalizing the Phase 3 ENSURE trials for relapsing multiple sclerosis, commencing the Phase 3 trial for primary progressive multiple sclerosis, and facilitating the transition into the next phase of the project."
datetime: "2026-02-13T11:32:57.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275895038.md)
  - [en](https://longbridge.com/en/news/275895038.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275895038.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/275895038.md) | [English](https://longbridge.com/en/news/275895038.md)


# Immunic raises USD 200 million in private placement, with potential for up to USD 200 million more. Funds to support Phase 3 trials and transition to commercial-stage company.

An initial sum of $200 million has been received upfront, with the possibility of an additional $200 million in proceeds. This funding is anticipated to cover the costs associated with finalizing the Phase 3 ENSURE trials for relapsing multiple sclerosis, commencing the Phase 3 trial for primary progressive multiple sclerosis, and facilitating the transition into the next phase of the project.

### 相關股票

- [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-HK/quote/ARKG.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-HK/quote/PBE.US.md)
- [Health Care Select Sector SPDR (XLV.US)](https://longbridge.com/zh-HK/quote/XLV.US.md)
- [VG Health (VHT.US)](https://longbridge.com/zh-HK/quote/VHT.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-HK/quote/IBB.US.md)
- [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-HK/quote/FBT.US.md)
- [iShares Global Healthcare (IXJ.US)](https://longbridge.com/zh-HK/quote/IXJ.US.md)
- [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-HK/quote/BIB.US.md)
- [Immunic (IMUX.US)](https://longbridge.com/zh-HK/quote/IMUX.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-HK/quote/BBH.US.md)
- [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-HK/quote/SBIO.US.md)
- [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-HK/quote/XBI.US.md)
- [iShares US Pharma (IHE.US)](https://longbridge.com/zh-HK/quote/IHE.US.md)

## 相關資訊與研究

- [Profound Medical Trial Shows TULSA Improves Prostate Cancer Outcomes](https://longbridge.com/zh-HK/news/279064417.md)
- [Pfizer Inc. Reports Positive Phase 2 Results for tilrekimig (PF-07275315) in Atopic Dermatitis](https://longbridge.com/zh-HK/news/278448836.md)
- [Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium | IMUX Stock News](https://longbridge.com/zh-HK/news/278536359.md)
- [Real-World Data Bolsters Oncopeptides’ Pepaxti as Bridging Therapy in Multiple Myeloma](https://longbridge.com/zh-HK/news/279027875.md)
- [Acurx Pharmaceuticals Q4 net loss narrows on lower R&D spend](https://longbridge.com/zh-HK/news/279032442.md)